Phaseline

Companies › Teligene US

Teligene US: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 3 Phase 2; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Sutetinib Maleate Capsule
EGFR tyrosine kinase inhibitor targeting uncommon mutations (L861Q, G719X, S768I)
EGFRPhase 2Non-small Cell Lung CancerDec 2027
TL118
NTRK fusion inhibitor
NTRK1, NTRK2, NTRK3Phase 2Solid TumorDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05168566Sutetinib Maleate CapsulePhase 2Non-small Cell Lung CancerOncologyDec 2027
NCT06010329Sutetinib Maleate CapsulePhase 2Non-small Cell Lung CancerOncologyDec 2027
NCT06010342TL118Phase 2Solid TumorOncologyDec 2027

Targets

EGFR (1) NTRK1 (1) NTRK2 (1) NTRK3 (1)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Bayer Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Xuanzhu Biopharmaceutical Dompé Farmaceutici Nuvation Bio Roche

Companies built like this

Wayshine Biopharm Black Diamond Therapeutics Avistone Biotechnology NanoEcho Syncromune

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.